The Experts below are selected from a list of 615 Experts worldwide ranked by ideXlab platform
Gunilla Wilen‐rosenqvist - One of the best experts on this subject based on the ideXlab platform.
-
Twice daily dosing of Erythromycin in the treatment of venereal chlamydial infections
Journal of the European Academy of Dermatology and Venereology, 1992Co-Authors: Lasse Lehtonen, Tuula Hirsjärvi‐lahti, Gunilla Wilen‐rosenqvistAbstract:Background. Tetracyclines are recommended as primary choice for the treatment of venereal chlamydial infections. Erythromycin has been used in high doses as an alternative. Erythromycin acistrate (EA) is a 2′-acetyl ester prodrug of Erythromycin that can be used in lower doses. Objective. To show the efficacy of EA 400 mg twice daily in the treatment of venereal chlamydial infections. Study design. A randomized, double-blind parallel group study. Chlamydia-positive patients were randomized to treatment with either EA or Erythromycin Stearate (ES) for 10 days. Follow up cultures were performed at 28 days after the start of therapy. The sexual consort was treated with Erythromycin Stearate. Subjects. A total of 151 patients participated (47 males, 104 females). Seventy-two patients received EA and 79 ES. Intervention. EA (0.4 g) and ES (0.5 g) were given twice daily for 10 days. Results. The bacteriological cure rate was 98% in the EA group and 97% in the ES group. There were no statistically significant differences between the treatment groups. No patient discontinued the medication in either group, although 30% of the EA group and 27% of the ES group reported adverse effects, mainly transient gastrointestinal symptoms. Main outcome. Treatment with Erythromycin acistrate or Stearate twice daily is a simple and efficient alternative for the treatment of sexually transmitted chlamydial infection in both male and female patients.
Zoltan Varga - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and tolerance of roxithromycin in comparison with Erythromycin Stearate in patients with lower respiratory tract infections.
Scandinavian journal of infectious diseases, 1992Co-Authors: Otto Paulsen, Bengt A. Christensson, Miroslav Hebelka, Bengt Ljungberg, Ingrid Nilsson-ehle, Lars Nyman, Rune Svensson, Peet Tüll, Zoltan VargaAbstract:The efficacy and tolerance of roxithromycin 150 mg b.i.d. were compared with those of Erythromycin Stearate 500 mg b.i.d. in patients with lower respiratory tract infections. Out of 86 patients recruited for the study, 79 were evaluable for tolerance and 76 for efficacy. These patients were evenly distributed among the 3 investigational clinics, with 26, 25 and 28 patients, respectively. The diagnosis of lower respiratory tract infections was based on clinical, laboratory, radiological and/or physical findings and, when available, bacteriological and serological findings. The duration of treatment was 10 days, with follow-up at post-treatment visits directly after treatment and 6 weeks thereafter. The clinical outcome was satisfactory with no significant difference between the drugs. More patients reporting adverse events were on Erythromycin than on roxithromycin (51.3% vs 17.5%; p = 0.003). The results suggest that roxithromycin is as effective as Erythromycin Stearate in the treatment of lower respiratory tract infections and causes fewer adverse effects.
Lasse Lehtonen - One of the best experts on this subject based on the ideXlab platform.
-
Twice daily dosing of Erythromycin in the treatment of venereal chlamydial infections
Journal of the European Academy of Dermatology and Venereology, 1992Co-Authors: Lasse Lehtonen, Tuula Hirsjärvi‐lahti, Gunilla Wilen‐rosenqvistAbstract:Background. Tetracyclines are recommended as primary choice for the treatment of venereal chlamydial infections. Erythromycin has been used in high doses as an alternative. Erythromycin acistrate (EA) is a 2′-acetyl ester prodrug of Erythromycin that can be used in lower doses. Objective. To show the efficacy of EA 400 mg twice daily in the treatment of venereal chlamydial infections. Study design. A randomized, double-blind parallel group study. Chlamydia-positive patients were randomized to treatment with either EA or Erythromycin Stearate (ES) for 10 days. Follow up cultures were performed at 28 days after the start of therapy. The sexual consort was treated with Erythromycin Stearate. Subjects. A total of 151 patients participated (47 males, 104 females). Seventy-two patients received EA and 79 ES. Intervention. EA (0.4 g) and ES (0.5 g) were given twice daily for 10 days. Results. The bacteriological cure rate was 98% in the EA group and 97% in the ES group. There were no statistically significant differences between the treatment groups. No patient discontinued the medication in either group, although 30% of the EA group and 27% of the ES group reported adverse effects, mainly transient gastrointestinal symptoms. Main outcome. Treatment with Erythromycin acistrate or Stearate twice daily is a simple and efficient alternative for the treatment of sexually transmitted chlamydial infection in both male and female patients.
Otto Paulsen - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and tolerance of roxithromycin in comparison with Erythromycin Stearate in patients with lower respiratory tract infections.
Scandinavian journal of infectious diseases, 1992Co-Authors: Otto Paulsen, Bengt A. Christensson, Miroslav Hebelka, Bengt Ljungberg, Ingrid Nilsson-ehle, Lars Nyman, Rune Svensson, Peet Tüll, Zoltan VargaAbstract:The efficacy and tolerance of roxithromycin 150 mg b.i.d. were compared with those of Erythromycin Stearate 500 mg b.i.d. in patients with lower respiratory tract infections. Out of 86 patients recruited for the study, 79 were evaluable for tolerance and 76 for efficacy. These patients were evenly distributed among the 3 investigational clinics, with 26, 25 and 28 patients, respectively. The diagnosis of lower respiratory tract infections was based on clinical, laboratory, radiological and/or physical findings and, when available, bacteriological and serological findings. The duration of treatment was 10 days, with follow-up at post-treatment visits directly after treatment and 6 weeks thereafter. The clinical outcome was satisfactory with no significant difference between the drugs. More patients reporting adverse events were on Erythromycin than on roxithromycin (51.3% vs 17.5%; p = 0.003). The results suggest that roxithromycin is as effective as Erythromycin Stearate in the treatment of lower respiratory tract infections and causes fewer adverse effects.
Kunle O. Olobayo - One of the best experts on this subject based on the ideXlab platform.
-
A new lipid-based oral delivery system of Erythromycin for prolong sustain release activity
Materials science & engineering. C Materials for biological applications, 2018Co-Authors: Ma Momoh, Emmanuel C. Ossai, Omeje E. Chidozie, Omenigbo O. Precscila, Franklin C. Kenechukwu, Kenneth O. Ofokansi, Anthony A. Attama, Kunle O. OlobayoAbstract:Abstract Erythromycin-loaded solid lipid microparticles (SLM) based on solidified reverse micellar solution (SRMS) as an oral delivery formulation was studied. Hot homogenization technique was employed to prepare Erythromycin Stearate-loaded SLMs using blends of Softisan® 154 and Phospholipon® 90H or beeswax in the ratio of 1:2, and characterized in vitro. Antibacterial evaluation of the formulations was carried out by agar diffusion technique against some selected clinical isolates of bacterial. Preliminary pharmacokinetic study was performed after oral administration in male Albino rats. The results of matrix contain Softisan® 154 and phospholipon® 90H (1:2) showed that Erythromycin-loaded SLM was smooth; particle size ranged from 10.3 ± 11.24 μm to 18.1 ± 10.11 μm and maximum encapsulation efficiency and loading capacity were 95.11 ± 0.3% and 43.22 ± 0.1 mg, respectively. While that of beeswax- containing matrix showed maximum particle size of 18.9 ± 21.10 μm, maximum encapsulation efficiency of 89.01 ± 0.11% and loading capacity of 39.02 ± 0.12 mg. All the formulations had prolonged release and antibacterial activity. Significantly (p > 0.05), prolonged plasma Erythromycin concentration was obtained in the optimized formulation (>14 h) compared with commercial sample of Erythromycin tablet (10h). Erythromycin Stearate-loaded SLMs formulation could serve as an alternative to conventional oral formulation of Erythromycin.